IDELALISIB (idelalisib) by Gilead Sciences is kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2026.
Drug data last refreshed 18h ago
Kinase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Worked on IDELALISIB at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.